We are searching for participants in clinical trials for MASH—short for Metabolic Dysfunction-Associated Steatohepatitis, previously known as NASH (Nonalcoholic Steatohepatitis). This serious liver condition is linked to obesity, Type 2 diabetes, high cholesterol, and metabolic syndrome, and can silently lead to liver scarring or failure if left untreated.
Our studies focus on evaluating new treatments to slow or reverse liver damage in people living with MASH. MASH is a progressive form of fatty liver disease caused by metabolic dysfunction. It occurs when:
- Excess fat builds up in the liver
- Inflammation and liver cell damage follow
- This can progress to fibrosis, cirrhosis, or even liver cancer
Unlike alcoholic liver disease, MASH occurs in people who do not consume excessive alcohol. Many people have no symptoms in early stages, which is why routine screening is critical for at-risk individuals. Possible symptoms may include:
- Fatigue
- Abdominal discomfort
- Elevated liver enzymes on routine lab tests
- Enlarged liver
- Signs of insulin resistance or metabolic syndrome
You may be at higher risk if you:
- Have Type 2 diabetes or prediabetes
- Are overweight or obese
- Have high blood pressure or high cholesterol
- Have been told you have fatty liver or elevated liver enzymes (ALT/AST)
- Have a family history of liver disease
Why Participate in a MASH Study?
- Access to investigational treatments not yet available to the public
- No cost for study-related care, imaging, or labs
- Close liver monitoring with FibroScan®, bloodwork, and regular follow-up
- Help advance critical research to treat a condition affecting millions globally
Compensation for time and travel may be offered. TBD
